Healthcare / Drug Manufacturers - Specialty & GenericToronto
$16.69
-0.15 (-0.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $19.5M · quality 82.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$424M
P/E
10.2x
↓EV/EBITDA
17.4x
↑ROE
21.6%
↑Gross Margin
80.1%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+34.6%
FCF CAGR
+40.5%
FCF margin
58.5%
FCF / Net income
1.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $50.5M · net income $27.3M · FCF $29.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $50.5M | $50.5M | $33.4M | $21.2M | $20.7M |
| Net Income | $27.3M | $27.3M | $11.5M | $20.4M | $26.6M |
| EBITDA | $24.1M | $24.1M | $11.9M | $11.5M | $12.0M |
| EPS | — | — | 0.46 | 0.80 | 1.03 |
| Gross Margin | 80.1% | 80.1% | 72.2% | 80.8% | 80.7% |
| Operating Margin | 33.4% | 33.4% | 23.5% | 48.7% | 53.4% |
| Net Margin | 54.2% | 54.2% | 34.6% | 96.3% | 128.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.40 | 0.00 | 0.01 |
| Current Ratio | 1.25 | 1.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $29.5M | $29.5M | $19.5M | $16.0M | $10.6M |
| Returns | |||||
| ROE | 21.6% | 21.6% | 11.3% | 25.3% | 41.6% |
| Valuation | |||||
| P/E | 10.18 | 10.18 | 31.35 | 7.76 | 3.74 |
| EV/EBITDA | 17.43 | 17.43 | 32.42 | 10.30 | 5.89 |
| P/B | 3.34 | 3.34 | 3.54 | 1.97 | 1.55 |
| Growth & Yield | |||||
| Revenue Growth | 51.2% | 51.2% | 57.7% | 2.4% | — |
| EPS Growth | — | — | -42.5% | -22.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.4%
Start / end P/E
n/dx → n/dx
EPS bridge
0.46 → n/d
Residual
+34.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.